GSK1016790A is a novel and potent transient receptor potential vanilloid 4 (TRPV4) activator.

Mavatrep (formerly known as JNJ-39439335) is a novel, orally bioavailable, potent and selective TRPV1 antagonist (Ki = 6.5 nM) with a potential to manage inflammatory pain.

RN1747 is a selective TRPV4 agonist (EC50 are 0.77, 4.0 and 4.1 μM for hTRPV4, mTRPV4 and rTRPV4 respectively).

Capsazepine is a novel, potent and synthetic antagonist of TRPM8 channels (IC50 = 562 nM) with potential anticancer activity.

BCTC is a selective and orally bioactive vanilloid receptor 1 (TRPV1 receptor) antagonist.

GFB-8438 is a novel, highly potent and subtype specific TRPC5 inhibitor with IC50s of 0.18 and 0.29 μM of hTRPC5 and hTRPC4, respectively.

Adarotene (ST-1926), a synthetic, phenolic hydroxyl retinoid with proapoptotic activity, is an atypical retinoid and a promising anti-tumour agent with selective apoptotic activity on the leukaemic blast.

ASP7663 is an selective and orally bioavailable TRPA1 activator, acting by stimulating 5-HT release from QGP-1 cells and exhibiting an abdominal analgesic effect in vivo.

AM-0902 is a novel, potent and selective Transient Receptor Potential A1 (TRPA1) antagonist with IC50s of 71 and 131 nM for rTRPA1 and hTRPA1, respectively.

BI-749327 (BI749327) is a novel, potent and orally bioavailable antagonist of Transient receptor potential canonical type 6 (TRPC6) with the potential to be used for treating PAH (pulmonary arterial hypertension) and PH (pulmonary hypertension) due to respiratory diseases or hypoxemia.